Joselyn Reyes

Learn More
OBJECTIVE To evaluate the long-term survival outcomes of a large cohort of liver transplant recipients and to identify static and changing factors that influenced these outcomes over time. SUMMARY BACKGROUND DATA Liver transplantation has been accepted as a therapeutic option for patients with end-stage liver disease since 1983, with continual(More)
A quantitative competitive PCR (QC-PCR) assay for Epstein-Barr virus (EBV) has been developed to provide accurate measurement of EBV genome load in pediatric transplant recipients at risk for developing posttransplant lymphoproliferative disorder (PTLD). The assay quantifies between 8 and 5,000 copies of the EBV genome in 10(5) lymphocytes after a 30-cycle(More)
The advent of tacrolimus allowed clinical intestinal transplantation to become a feasible procedure for patients with irreversible intestinal failure. Over last 5 years, 71 patients underwent intestinal transplantation. Forty-one recipients were children, and 30 recipients were adults. Twenty-five patients received an isolated intestinal graft, 34 patients(More)
BACKGROUND Bacterial translocation (BT) has been suggested to be responsible for the high incidence of infections occurring after small bowel transplantation (SBTx). Bacterial overgrowth, alteration of the mucosal barrier function as a consequence of preservation injury or acute rejection (AR), and potent immunosuppression are all associated with BT. The(More)
Pediatric solid organ transplant recipients are at risk for Epstein-Barr virus (EBV)-driven lymphoproliferative disease. The expression of 5 sentinel EBV genes (EBNA1, EBNA2a, LMP1, LMP2a, and ZEBRA) was examined in solid organ transplant recipients who developed persistent virus loads in their peripheral blood lymphocytes after transplantation. Two(More)
OBJECTIVE To summarize the long-term efficacy and safety of tacrolimus in orthotopic liver transplant (OLT) recipients, as well as to examine the factors that influence long-term morbidity and mortality rates. BACKGROUND Tacrolimus (FK506, Prograf) was introduced as primary immunosuppression for primary liver transplantation in 1989; many subsequent(More)
The principal side effects of the new immunosuppressive drug FK506 have been low-grade nephrotoxicity, a mild diabe-togenic effect. and annoying but relatively minor manifestations of neurotoxicity (1). The neurotoxic symptoms have included tremors, paresthesias, insomnia, headaches. increased visual sensitivity to light, nightmares, a sense of racing, and(More)
Chronic renal failure (CRF) patients are considered to present genomic instability and, as a consequence, elevated levels of genetic damage. An open question is whether this damage is related to the stage of the pathology. To determine the background levels of genetic damage, a large population of 258 Caucasian adults (201 CRF patients and 57 controls) was(More)
F K 506 is a powerful new investigational immunosup-. pressant that has been used successfully first as an organ rescue agent and then as a primary antirejection agent. FK 506 has been shown to have a favorable profile on pancreatic islets in vitro'; however, the agent does decrease glucose-induced insulin release at high concentrations from bo~ rodent 2 •(More)
F K 506 (Tanolimus. Prograf'") has been recently approved by the Food and Drug Administration (FDA) for baseline immunosuppression following orthotopic liver transplantation (OLT). The drug was first used clinically in 1990. extensive reports were given from our center describing the potential value of this drug in clinical transplanta-tion.~·' We have so(More)